Sandoz stock: mAbxience agreement expands biosimilar pipeline to 40 assets

Sandoz announced a September 18 collaboration with mAbxience for an emicizumab biosimilar. The agreement expands its biosimilar pipeline to 40 assets.

Sandoz announced on September 18, 2026, a licensing, development, manufacturing and commercialization agreement with mAbxience for a proposed emicizumab biosimilar. The candidate is in early-stage development and would target hemophilia A. EQS News reported the issuer's release.

Collaboration terms

Under the agreement, Sandoz will have exclusive global commercialization rights for the proposed biosimilar, excluding Argentina, Uruguay and Paraguay. mAbxience will be responsible for development and manufacturing, while the companies will keep the financial terms confidential. EQS News published the terms.

Pipeline expansion

Sandoz said the collaboration expands its biosimilar pipeline to 40 assets. The company also said the reference medicine's global market was estimated at USD 5.7 billion in sales. EQS News carried the company announcement.